BioCentury | Mar 4, 2019
Company News

Management tracks: Astellas, Sanofi China, Zafgen

...Calif.) hired Todd Wood as chief commercial officer. He was VP of global sales at Obalon Therapeutics Inc....
BioCentury | Mar 17, 2017
Finance

Mirae’s Western expansion

...U.S. biotechs: immuno-oncology company ImmunoMet Therapeutics ; autoimmune company Neothetics Inc. (NASDAQ:NEOT); and endocrine/metabolic company Obalon Therapeutics Inc....
BioCentury | Jan 6, 2017
Finance

Good riddance

...NASDAQ:CRSP) 10/18/16 $62.0 $557.1 $806.5 45% AzurRx BioPharma Inc. (NASDAQ:AZRX) 10/11/16 $5.3 $53.0 $45.7 -14% Obalon Therapeutics Inc....
BioCentury | Oct 10, 2016
Financial News

Obalon Therapeutics completes IPO

Obalon Therapeutics Inc. (NASDAQ:OBLN), Carlsbad, Calif. Business: Endocrine/Metabolic Date completed: 2016-10-05 Type: IPO Raised: $75 million Shares: 5 million Price: $15 Shares after offering: 16 million Underwriters: UBS; Canaccord; Stifel, Nicolaus; BTIG Overallotment: 750,000 WIR...
BioCentury | Oct 3, 2016
Finance

Reasonable rally

...Ltd. (TPEx-E:6472) (C) 9/23/16 TBD Mkt (drug) CRISPR Therapeutics AG 9/9/16 Up to $90M Preclin Obalon Therapeutics Inc....
BioCentury | Oct 3, 2016
Financial News

Obalon Therapeutics amends IPO

Obalon Therapeutics Inc. , Carlsbad, Calif. Business: Endocrine/Metabolic Date announced: 2016-09-26 Type: IPO To be raised: Up to $80 million Shares: 5 million Price: $14-$16 Underwriters: UBS; Canaccord; Stifel, Nicolaus; BTIG Overallotment: 750,000 Note: Obalon amended...
BioCentury | Oct 3, 2016
Financial News

Obalon Therapeutics amends IPO

Obalon Therapeutics Inc. , Carlsbad, Calif. Business: Endocrine/Metabolic Date announced: 2016-09-26 Type: IPO To be raised: Up to $80 million Shares: 5 million Price: $14-$16 Underwriters: UBS; Canaccord; Stifel, Nicolaus; BTIG Overallotment: 750,000 Note: Obalon amended...
BioCentury | Sep 12, 2016
Financial News

Obalon Therapeutics proposes IPO

Obalon Therapeutics Inc. , Carlsbad, Calif. Business: Endocrine/Metabolic Date announced: 2016-09-09 Type: IPO To be raised: Up to $75 million Shares: TBD Price: TBD Underwriters: UBS; Canaccord; Stifel, Nicolaus; BTIG Note: Obalon is seeking to list...
BioCentury | Jan 19, 2015
Financial News

Obalon Therapeutics completes venture financing

Obalon Therapeutics Inc. , Carlsbad, Calif. Business: Endocrine/Metabolic Date completed: 2015-01-14 Type: Venture financing Raised: $20 million Investors: Axon Ventures; Bader Sultan & Bros.; Mirae Asset Venture Investment; NeoPlux; Striker Asia Opportunities Fund; Domain Associates; InterWest...
BioCentury | Jan 19, 2015
Financial News

Obalon Therapeutics financial update

Obalon Therapeutics Inc. , Carlsbad, Calif. Business: Endocrine/Metabolic Date announced: 2015-01-14 Note: Obalon secured a loan facility for up to $10 million from Square 1 Bank. The company declined to disclose if any funds had been...
Items per page:
1 - 10 of 10
BioCentury | Mar 4, 2019
Company News

Management tracks: Astellas, Sanofi China, Zafgen

...Calif.) hired Todd Wood as chief commercial officer. He was VP of global sales at Obalon Therapeutics Inc....
BioCentury | Mar 17, 2017
Finance

Mirae’s Western expansion

...U.S. biotechs: immuno-oncology company ImmunoMet Therapeutics ; autoimmune company Neothetics Inc. (NASDAQ:NEOT); and endocrine/metabolic company Obalon Therapeutics Inc....
BioCentury | Jan 6, 2017
Finance

Good riddance

...NASDAQ:CRSP) 10/18/16 $62.0 $557.1 $806.5 45% AzurRx BioPharma Inc. (NASDAQ:AZRX) 10/11/16 $5.3 $53.0 $45.7 -14% Obalon Therapeutics Inc....
BioCentury | Oct 10, 2016
Financial News

Obalon Therapeutics completes IPO

Obalon Therapeutics Inc. (NASDAQ:OBLN), Carlsbad, Calif. Business: Endocrine/Metabolic Date completed: 2016-10-05 Type: IPO Raised: $75 million Shares: 5 million Price: $15 Shares after offering: 16 million Underwriters: UBS; Canaccord; Stifel, Nicolaus; BTIG Overallotment: 750,000 WIR...
BioCentury | Oct 3, 2016
Finance

Reasonable rally

...Ltd. (TPEx-E:6472) (C) 9/23/16 TBD Mkt (drug) CRISPR Therapeutics AG 9/9/16 Up to $90M Preclin Obalon Therapeutics Inc....
BioCentury | Oct 3, 2016
Financial News

Obalon Therapeutics amends IPO

Obalon Therapeutics Inc. , Carlsbad, Calif. Business: Endocrine/Metabolic Date announced: 2016-09-26 Type: IPO To be raised: Up to $80 million Shares: 5 million Price: $14-$16 Underwriters: UBS; Canaccord; Stifel, Nicolaus; BTIG Overallotment: 750,000 Note: Obalon amended...
BioCentury | Oct 3, 2016
Financial News

Obalon Therapeutics amends IPO

Obalon Therapeutics Inc. , Carlsbad, Calif. Business: Endocrine/Metabolic Date announced: 2016-09-26 Type: IPO To be raised: Up to $80 million Shares: 5 million Price: $14-$16 Underwriters: UBS; Canaccord; Stifel, Nicolaus; BTIG Overallotment: 750,000 Note: Obalon amended...
BioCentury | Sep 12, 2016
Financial News

Obalon Therapeutics proposes IPO

Obalon Therapeutics Inc. , Carlsbad, Calif. Business: Endocrine/Metabolic Date announced: 2016-09-09 Type: IPO To be raised: Up to $75 million Shares: TBD Price: TBD Underwriters: UBS; Canaccord; Stifel, Nicolaus; BTIG Note: Obalon is seeking to list...
BioCentury | Jan 19, 2015
Financial News

Obalon Therapeutics completes venture financing

Obalon Therapeutics Inc. , Carlsbad, Calif. Business: Endocrine/Metabolic Date completed: 2015-01-14 Type: Venture financing Raised: $20 million Investors: Axon Ventures; Bader Sultan & Bros.; Mirae Asset Venture Investment; NeoPlux; Striker Asia Opportunities Fund; Domain Associates; InterWest...
BioCentury | Jan 19, 2015
Financial News

Obalon Therapeutics financial update

Obalon Therapeutics Inc. , Carlsbad, Calif. Business: Endocrine/Metabolic Date announced: 2015-01-14 Note: Obalon secured a loan facility for up to $10 million from Square 1 Bank. The company declined to disclose if any funds had been...
Items per page:
1 - 10 of 10